How Huawei smartwatches aim to spot early diabetes risk trends
Huawei highlighted recent research pointing to a shared genetic relationship between resting heart rate and diabetes
11 February, 2026
TT
16
Huawei showcased new wearable-led wellness insights focused on blood sugar management at World Health Expo Dubai 2026, highlighting how non-invasive technology can support early awareness of potential diabetes risks.
The feature leverages Photoplethysmography (PPG) technology and advanced sensors embedded in Huawei smartwatches to analyse changes in PPG signals and generate proactive wellness alerts. Huawei said the function is designed to raise awareness of possible blood sugar-related trends and encourage users to seek early medical consultation, rather than deliver medical diagnoses.
According to the 2024 report by the International Diabetes Federation (IDF), 589 million adults aged between 20 and 79 are living with diabetes globally. An estimated 43 per cent of cases remain undiagnosed, while 81 per cent of people with diabetes live in low- and middle-income countries. In the Middle East and North Africa, 85 million adults currently have diabetes, with the figure projected to rise by 92 per cent to 163 million by 2050. In the UAE, diabetes prevalence among adults stands at 20.7 per cent.
Huawei highlighted recent research pointing to a shared genetic relationship between resting heart rate and diabetes, as well as findings that diabetes-related microvascular arteriosclerosis and neuropathy can influence PPG signals. Based on these mechanisms, the company developed a wellness feature that identifies potential blood sugar fluctuations by analysing PPG data collected through smartwatch usage.
To activate the feature, users are required to wear the smartwatch consistently for a period ranging from three to 14 days. Once sufficient data is gathered, the Diabetes Risk app categorises wellness patterns into Low, Medium, or High. Huawei recommends that users flagged under Medium or High patterns seek professional medical evaluation for further assessment, positioning the feature as a preventative awareness tool rather than a diagnostic solution.
Professor Jiguang Wang, director of the Shanghai Institute of Hypertension, addressed the event, highlighting the growing role of wearable-based PPG technology in proactive health trend awareness. Professor Wang has worked closely with Huawei on advancing wearable health management and contributed to the development of the HUAWEI WATCH D and HUAWEI WATCH D2, the company’s blood pressure monitoring smartwatches.
Huawei confirmed that the feature is already available via an over-the-air update on the HUAWEI WATCH GT 6 Pro, with plans to expand compatibility across additional smartwatch models. While the feature is safe for general use and carries no known side effects or contraindications, Huawei emphasised that it does not replace professional diabetes diagnostics or clinical testing.
Read: From policy to patients: How the UAE is scaling healthcare innovation at WHX 2026


















